Navigation Links
Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
Date:5/1/2012

affect the Company's actual results: the integration of the acquired companies, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission.  We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Use of Adjusted Financial Measures:
The adjusted financial measures used in this press release quantify the impact the following events had on reported net sales, gross margin percentages, selling, general and administrative expenses, net earnings and earnings per share for the quarter and nine-month period ended March 31, 2012 as compared to the reported amounts for the same periods ended March 31, 2011:

  • fluctuations in exchange rates used to convert transactions in foreign currencies (primarily the Euro, British pound sterling and Chinese yuan) to U.S. dollars;
  • the acquisitions of Boston Biochem on April 1, 2011 and Tocris on April 28, 2011, including the impact of amortizing intangible assets and the recognition of costs upon the sale of inventory written-up to fair  value;
  • impairment losses related to
    '/>"/>

    • SOURCE Techne Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Techne Corporation Declares Dividend
    2. Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results
    3. Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results
    4. Technest Holdings, Inc. to Acquire AccelPath, LLC; Issue Contingent Value Rights to Common Stockholders; and Issue Shares of Its Series E 5% Convertible Preferred Stock
    5. Techne Corporation Declares Dividend
    6. Techne Corporation Declares Dividend
    7. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
    8. Luminex Corporation Reports First Quarter 2012 Results
    9. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
    10. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
    11. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/18/2013)... 18, 2013 Decision Resources, one of the world,s ... finds that, over the past 12 months, 25 percent of ... Germany , Italy , ... Kingdom ) have been required to change the antiretroviral ... primarily to reduce costs. Additionally, more than 40 percent of ...
    (Date:6/18/2013)... YORK , June 18, 2013 JDRF and ... are accelerating the development of new products that combine BD,s ... collaboration announced today. This new, three-year commitment is an extension ... Many patients with T1D not only take daily ... be placed in the body for a number of days ...
    (Date:6/18/2013)... 18, 2013 Today, Wall Street Reports ... GILD ), Health Management Associates Inc. (NYSE: ... ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius ... free of charge - including full price targets, industry analysis ... Gilead Sciences, Inc. Research Report On June 7, ...
    Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
    ... presented at,the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) ... continue,to offer new and better treatment options for breast ... for longer if the medicines are,given before and after ... , , Key data ...
    ... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced ... AZ-004 (Staccato(R) loxapine). This Phase 3,clinical trial was ... Both the 5 mg and 10 mg doses of ... a statistically significant reduction in,agitation from baseline to the ...
    Cached Medicine Technology:New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer 2New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer 3New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer 4Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 2Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 4Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 5Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 6Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 7Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 8Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 9Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 10
    (Date:6/18/2013)... York (PRWEB) June 19, 2013 Parker ... the rights of victims injured by dangerous drugs and ... an Arizona woman who alleges that she was ... filed on May 30th in the U.S. District Court ... No. 2:13-cv-12677) in the multidistrict litigation entitled In Re: ...
    (Date:6/18/2013)... Colorado (PRWEB) June 18, 2013 Daily Gossip ... latest product reviews and useful articles. , The magazine ... introducing them to a new anabolic recipe every week ... Book is the perfect guide for readers who are ... , Reporters at Daily Gossip reveals that anabolic food is ...
    (Date:6/18/2013)... 18, 2013 The Temp1000IS temperature ... stand-alone device which can be used to automatically record ... enclosure of the Temp1000IS comes with the serial number ... IFC400 (sold separately) docking station and can ... communications. No more removal of end-caps to download data. ...
    (Date:6/18/2013)... Palo Alto has taken yet another step in ... its recent major long-term solar power commitment. , Last ... power purchase agreements , which together will result in the ... electric power per year, which is the equivalent of roughly ... power to supply all 65,000+ Palo Alto residents---and then some! ...
    (Date:6/18/2013)... 18, 2013 Internationally acclaimed plastic ... website, thebestbreast.com, showcasing his unique approach to breast ... about his surgical method and highlights the results ... his website, Dr. Tebbetts compares his breast augmentation ... Dr. Tebbetts’ method does not necessitate the use ...
    Breaking Medicine News(10 mins):Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2
    ... visually impaired, navigating city streets or neighborhoods has constant challenges. ... rudimentary technologya simple caneto help them make their way through ... California engineering researchers is working to change that by developing ... design first shown a year ago is now being further ...
    ... Steven Reinberg HealthDay Reporter , WEDNESDAY, May ... prescribed drugs, the antidepressant Paxil and the cholesterol-lowering medication ... new study finds. The increase is most apparent ... is already too high, the researchers noted. "This ...
    ... 2011) The Maryland Stem Cell Research Commission (Commission) ... in response to its three FY 2011 Requests for ... Technology Development Corporation (TEDCO) approved the Commission,s recommendation to ... Research Fund,s (MSCRF) $10.4 million FY 2011 budget. ...
    ... May 25 (HealthDay News) -- The Internet has put the ... also allowed banned or controlled substances to slip within their ... online May 19 in Drug Testing and Analysis , ... contain ingredients other than those claimed and can be hazardous. ...
    ... obese women with less-than-optimal levels of vitamin D who lose ... increases in circulating levels of this fat-soluble nutrient, according to ... Center. , "Since vitamin D is generally lower in persons ... account, in part, for the link between obesity and diseases ...
    ... known for years that playing violent video games causes ... a new University of Missouri (MU) study provide one ... video game players become less responsive to violence, and ... "Many researchers have believed that becoming desensitized to ...
    Cached Medicine News:Health News:'Guide vests' -- robotic navigation aids for the visually impaired 2Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 2Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 3Health News:Maryland Stem Cell Research Commission funds 36 new projects in FY 2011 2Health News:Maryland Stem Cell Research Commission funds 36 new projects in FY 2011 3Health News:Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 3Health News:Violent video games reduce brain response to violence and increase aggressive behavior 2
    Inquire...
    Inquire...
    ... Anatomical Malar I Implants - Providing ... implant follows the contour of the zygoma ... prominence. Anatomical Malar II Implants - ... the surgeon with another augumentation option that ...
    ... - Anatomically designed to enhance the chin contour, ... mandible with a high-profile central chin projection. ... entire mandible, this implant provides a high central ... arms. Cleft Chin Implants - Designed with ...
    Medicine Products: